<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPR</journal-id>
<journal-id journal-id-type="hwp">spcpr</journal-id>
<journal-id journal-id-type="nlm-ta">Eur J Cardiovasc Prev Rehabil</journal-id>
    <journal-title>European Journal of Preventive Cardiology</journal-title>
<issn pub-type="ppub">2047-4873</issn>
<issn pub-type="epub">2047-4881</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1741826711428243</article-id>
<article-id pub-id-type="publisher-id">10.1177_1741826711428243</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Myocardial infarction</subject>
<subj-group subj-group-type="heading">
<subject>Original scientific paper</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>The prognostic role of chronic obstructive pulmonary disease in ST-elevation myocardial infarction after primary angioplasty</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Lazzeri</surname><given-names>Chiara</given-names></name>
<xref ref-type="corresp" rid="corresp1-1741826711428243"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Valente</surname><given-names>Serafina</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Attanà</surname><given-names>Paola</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Chiostri</surname><given-names>Marco</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Picariello</surname><given-names>Claudio</given-names></name>
</contrib>
<contrib contrib-type="author">
<name><surname>Gensini</surname><given-names>Gian Franco</given-names></name>
</contrib>
</contrib-group>
<aff id="aff1-1741826711428243">Ospedaliero-Universitaria Careggi, Florence, Italy</aff>
<author-notes>
<corresp id="corresp1-1741826711428243">Chiara Lazzeri, Intensive Cardiac Care Unit, Heart and Vessel Department, Viale Morgagni 85, 50134 Florence, Italy Email: <email>lazzeric@libero.it</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>20</volume>
<issue>3</issue>
<fpage>392</fpage>
<lpage>398</lpage>
<history>
<date date-type="received"><day>14</day><month>5</month><year>2011</year></date>
<date date-type="accepted"><day>10</day><month>10</month><year>2011</year></date>
</history>
<permissions>
<copyright-statement>© The European Society of Cardiology 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="society">European Society of Cardiology</copyright-holder>
</permissions>
<abstract>
<sec id="sec9-1741826711428243"><title>Background:</title><p>Chronic obstructive pulmonary disease (COPD) has been reported as a common finding in patients with acute myocardial infarction but data on its prognostic role are still controversial.</p></sec>
<sec id="sec10-1741826711428243"><title>Methods:</title><p>The present investigation was aimed at assessing the impact of COPD at short and long terms in 818 consecutive patients with ST-elevation myocardial infarction all submitted to percutaneous coronary intervention.</p></sec>
<sec id="sec11-1741826711428243"><title>Results:</title><p>Patients with COPD were older (<italic>p</italic> &lt; 0.001) and more frequently smokers (<italic>p</italic> = 0.019). They showed a reduced estimated glomerular filtration rate (eGFR; <italic>p</italic> = 0.004) and a higher incidence of a more advanced coronary artery disease (<italic>p</italic> = 0.004). Patients with COPD showed higher values of N-terminal pro-brain natriuretic peptide (<italic>p</italic> = 0.004), uric acid (<italic>p</italic> = 0.005), erythrocyte sedimentation rate (<italic>p</italic> = 0.002), fibrinogen (<italic>p</italic> = 0.004), and C-reactive protein positivity (<italic>p</italic> = 0.017). Kaplan−Meier survival curve documented a significantly worse outcome in COPD patients. When age was taken into account, COPD patients aged &lt;75 years showed a significantly worse outcome at follow up when compared to non-COPD patients aged &lt;75 years. At multivariate analysis, the following variables were independent predictors for death at follow up: age, eGFR, COPD, and discharge left ventricular ejection fraction.</p></sec>
<sec id="sec12-1741826711428243"><title>Conclusions:</title><p>In our series, while the presence of COPD was not significantly associated with an increased early mortality, COPD is an independent predictor of long-term mortality. In particular, long-term survival was significantly poorer in COPD patients &lt;75 years in respect to non-COPD patients with the same age. Our data strongly suggest that age should be taken into account in the risk stratification of COPD patients with ST-elevation myocardial infarction.</p></sec>
</abstract>
<kwd-group>
<kwd>Age</kwd>
<kwd>COPD</kwd>
<kwd>prognosis</kwd>
<kwd>STEMI</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-1741826711428243" sec-type="intro"><title>Introduction</title>
<p>The presence of chronic obstructive pulmonary disease (COPD) is associated with a two- to threefold greater risk of cardiovascular death, which in turn is responsible for about a half of all COPD deaths.<sup><xref ref-type="bibr" rid="bibr1-1741826711428243">1</xref></sup></p>
<p>COPD has been reported as a common finding in patients with acute myocardial infarction (AMI).<sup><xref ref-type="bibr" rid="bibr2-1741826711428243">2</xref><xref ref-type="bibr" rid="bibr3-1741826711428243"/><xref ref-type="bibr" rid="bibr4-1741826711428243"/><xref ref-type="bibr" rid="bibr5-1741826711428243"/>–<xref ref-type="bibr" rid="bibr6-1741826711428243">6</xref></sup> Few studies investigated the impact of COPD at short and long terms in patients with AMI, with controversial results. Discrepancies may be related to differences in patient selection criteria and/or in strategies of revascularization, as well as in sample size. Most studies were performed in the thrombolytic era and COPD patients with AMI were less frequently submitted to revascularization in comparison with non-COPD patients.</p>
<p>The present investigation was aimed at assessing the impact of COPD at short and long terms in 818 consecutive patients with ST-elevation myocardial infarction (STEMI) all submitted to percutaneous coronary intervention (PCI).</p>
</sec>
<sec id="sec2-1741826711428243" sec-type="methods"><title>Methods</title>
<sec id="sec3-1741826711428243"><title>Study population</title>
<p>From 1 January 2005 to 31 December 2009, 818 consecutive patients with STEMI (within 12 hours from symptom onset) and without previously known diabetes were admitted to our intensive cardiac care unit (ICCU), which is located at a tertiary centre. In our hospital, in Florence, the reperfusion strategy of STEMI patients is represented by primary PCI.<sup><xref ref-type="bibr" rid="bibr7-1741826711428243">7</xref><xref ref-type="bibr" rid="bibr8-1741826711428243"/><xref ref-type="bibr" rid="bibr9-1741826711428243"/><xref ref-type="bibr" rid="bibr10-1741826711428243"/>–<xref ref-type="bibr" rid="bibr11-1741826711428243">11</xref></sup> STEMI patients are first evaluated by the medical emergency system staff in the prehospital setting and then directly admitted to the catheterization laboratory or transferred to it after a rapid stabilization in First Aid<italic>.</italic> After primary PCI, they are admitted to our ICCU.</p>
<p>A successful procedure was defined as an infarct artery stenosis &lt;20% associated with thrombolysis in myocardial infarction (TIMI) grade 3 flow. Failure PCI was defined as resulting in TIMI grade 0−2 flow, regardless the residual stenosis.<sup><xref ref-type="bibr" rid="bibr12-1741826711428243">12</xref></sup> The diagnosis of STEMI was based on the criteria of the American College of Cardiology/American Heart Association.<sup><xref ref-type="bibr" rid="bibr12-1741826711428243">12</xref>,<xref ref-type="bibr" rid="bibr13-1741826711428243">13</xref></sup></p>
<p>On ICCU admission, after PCI, in a fasting blood sample the following parameters were measured: glucose (mg/dl), insulin values (IU/l),<sup><xref ref-type="bibr" rid="bibr8-1741826711428243">8</xref>,<xref ref-type="bibr" rid="bibr10-1741826711428243">10</xref></sup> C-peptide (ng/ml), HbA1c (%) troponin I (TnI, ng/ml), uric acid (mg/dl),<sup><xref ref-type="bibr" rid="bibr14-1741826711428243">14</xref></sup> C-reactive protein (CRP, mg/dl, normal values &lt;9), alanine aminotransferase (IU/l), aspartate aminotransferase (IU/l),<sup><xref ref-type="bibr" rid="bibr15-1741826711428243">15</xref></sup> gamma-glutamyl transferase (IU/l),<sup><xref ref-type="bibr" rid="bibr16-1741826711428243">16</xref></sup> NT-pro-brain natriuretic peptide (NT-pro-BNP, pg/ml)<sup><xref ref-type="bibr" rid="bibr7-1741826711428243">7</xref></sup> total cholesterol (mg/dl), triglycerides (mg/dl), high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and fibrinogen (mg/dl). Creatinine (mg/dl) was also measured in order to calculate estimated glomerular filtration rate (eGFR, ml/min/1.73 m<sup>2</sup>).<sup><xref ref-type="bibr" rid="bibr17-1741826711428243">17</xref></sup> Glucose and TnI were measured three times a day during ICCU stay and peak values for each variable were considered.<sup><xref ref-type="bibr" rid="bibr18-1741826711428243">18</xref></sup> Insulin resistance was evaluated by means of the Homeostatic Model Assessment (HOMA) index, as previously described.<sup><xref ref-type="bibr" rid="bibr8-1741826711428243">8</xref>,<xref ref-type="bibr" rid="bibr10-1741826711428243">10</xref>,<xref ref-type="bibr" rid="bibr19-1741826711428243">19</xref>,<xref ref-type="bibr" rid="bibr20-1741826711428243">20</xref></sup> HOMA was calculated according to the following formula: {[fasting insulin (µU/ml)] × [fasting glucose (mmol/l)]}/22.5. Subjects whose values exceeded the sex-specific 75th percentile (i.e. 1.80 for women and 2.12 for men) were considered to have insulin resistance.</p>
<p>Transthoracic two-dimensional echocardiography was performed on ICCU admission and at discharge in order to measure left ventricular ejection fraction (LVEF). LVEF was determined using the modified biplane Simpson's method by orthogonal apical views (two and four chambers), using mean values of three cardiac cycles.<sup><xref ref-type="bibr" rid="bibr21-1741826711428243">21</xref></sup></p>
<p>Major bleedings were defined according to the ACUITY criteria:<sup><xref ref-type="bibr" rid="bibr22-1741826711428243">22</xref></sup> intracranial or intraocular bleeding; access-site haemorrhage requiring intervention, ≥5-cm diameter haematoma, clinically overt blood loss with haemoglobin decrease ≥3 g/dl, any haemoglobin decrease ≥4 g/dl, or blood-product transfusion. COPD was defined as the reported need for pharmacological therapy and/or a 1-second forced expiratory volume &lt;70% of the predictive value.<sup><xref ref-type="bibr" rid="bibr7-1741826711428243">7</xref>,<xref ref-type="bibr" rid="bibr23-1741826711428243">23</xref></sup> Accordingly, 71 of the 818 (8.7%) were considered to have COPD before the index hospital admission.</p>
<p>The study protocol was in accordance with the Declaration of Helsinki and approved by the local Ethics Committee. Informed consent was obtained in all patients before enrolment.</p>
</sec>
<sec id="sec4-1741826711428243"><title>Statistical analysis</title>
<p>Statistical analysis was performed using SPSS for Windows, version 13.0 (SPSS, Inc., Chicago, Illinois). A <italic>p</italic>-value &lt;0.05 was considered statistically significant. Data are expressed as frequencies and percentages, or median (25−75th percentile). To evaluate differences in clinical, biohumoral and angiographic data, patients were divided in groups according to the presence or not of COPD and according to their age (categorically defined as ≥75 and &lt;75 years). Chi-squared (or Fisher’s exact test when needed) and Mann−Whitney <italic>U</italic> tests were used for univariate analysis. Kaplan−Meier survival analyses were performed to evaluate differences in mortality during follow up in relation to COPD; the same analysis was performed in the two age classes. Differences were assessed by means of log-rank test. After assessment of risk proportionality, several univariate Cox regression analyses were performed to investigate relationships of anamnestic, clinical, and biohumoral variables with long-term death. To examine potential adjusted predictors of mortality at follow up, baseline variables that were considered clinically relevant or that showed a univariate relationship with outcome were entered into a multivariate Cox proportional hazards regression model. Variables for inclusion were carefully chosen, given the number of events available, to ensure parsimony of the final models; COPD was forced into the final model. Nonsignificant variables were dropped by means of backward selection.</p>
</sec>
</sec>
<sec id="sec5-1741826711428243" sec-type="results"><title>Results</title>
<p>The clinical characteristics of 818 patients with STEMI included in the study are shown in <xref ref-type="table" rid="table1-1741826711428243">Table 1</xref>. Patients with COPD were older (<italic>p</italic> &lt; 0.001) and more frequently smokers (<italic>p</italic> = 0.019). They showed a reduced eGFR (<italic>p</italic> = 0.004) and a higher incidence of a more advanced coronary artery disease (<italic>p</italic> = 0.004). In the comparison between patients with and without COPD, no significant difference was detectable in AMI location, in the incidence of PCI failure, latency, and in-ICCU mortality.
<table-wrap id="table1-1741826711428243" position="float"><label>Table 1.</label><caption><p>Clinical characteristics of 818 patients with ST-elevation myocardial infarction included in the study</p></caption>
<graphic alternate-form-of="table1-1741826711428243" xlink:href="10.1177_1741826711428243-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>COPD (<italic>n</italic> = 71)</th>
<th>No COPD (<italic>n</italic> = 747)</th>
<th><italic>p</italic>-value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Age (years)</td>
<td>74 (69–81)</td>
<td>67 (58–76)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Males/females</td>
<td>47/24 (66.2/33.8)</td>
<td>547/200 (73.2/26.8)</td>
<td>0.204</td>
</tr>
<tr>
<td>History of:</td>
</tr>
<tr>
<td> Smoking</td>
<td>54 (76.1)</td>
<td>461 (61.7)</td>
<td>0.019</td>
</tr>
<tr>
<td> Previous PCI</td>
<td>11 (15.5)</td>
<td>102 (13.7)</td>
<td>0.668</td>
</tr>
<tr>
<td> Previous MI</td>
<td>15 (21.1)</td>
<td>100 (13.4)</td>
<td>0.073</td>
</tr>
<tr>
<td> Diabetes</td>
<td>24 (33.8)</td>
<td>200 (26.8)</td>
<td>0.204</td>
</tr>
<tr>
<td> Hypertension</td>
<td>45 (63.4)</td>
<td>400 (53.5)</td>
<td>0.093</td>
</tr>
<tr>
<td>eGFR (ml/min/1.73 m<sup>2</sup>)</td>
<td>70.0 (50.6–89.6)</td>
<td>79.6 (65.2–94.7)</td>
<td>0.004</td>
</tr>
<tr>
<td>AMI location</td>
</tr>
<tr>
<td> Anterior</td>
<td>29 (40.8)</td>
<td>390 (52.2)</td>
<td>0.181</td>
</tr>
<tr>
<td> Inferior</td>
<td>36 (50.7)</td>
<td>301 (40.3)</td>
</tr>
<tr>
<td> Other</td>
<td>6 (8.5)</td>
<td>56 (7.5)</td>
</tr>
<tr>
<td>Coronary artery disease</td>
</tr>
<tr>
<td> 1-vessel</td>
<td>18 (25.4)</td>
<td>296 (39.6)</td>
<td>0.042<sup><xref ref-type="table-fn" rid="table-fn1-1741826711428243">a</xref></sup></td>
</tr>
<tr>
<td> 2-vessel</td>
<td>32 (45.1)</td>
<td>246 (32.9)</td>
</tr>
<tr>
<td> 3-vessel</td>
<td>21 (29.6)</td>
<td>205 (27.4)</td>
</tr>
<tr>
<td>LM involvement</td>
<td>3 (4.2)</td>
<td>59 (8.0)</td>
<td>0.257</td>
</tr>
<tr>
<td>CABG involvement</td>
<td>2 (2.8)</td>
<td>10 (1.3)</td>
<td>0.280<sup><xref ref-type="table-fn" rid="table-fn1-1741826711428243">b</xref></sup></td>
</tr>
<tr>
<td>PCI failure</td>
<td>5 (7.0)</td>
<td>53 (7.1)</td>
<td>0.990</td>
</tr>
<tr>
<td>Admission ejection fraction</td>
<td>45 (36.5–52)</td>
<td>45 (35–50)</td>
<td>0.661</td>
</tr>
<tr>
<td>Door-to-balloon time (mins)</td>
<td>180 (140–360)</td>
<td>230 (160–303)</td>
<td>0.314</td>
</tr>
<tr>
<td>Length of stay (hours)</td>
<td>66 (44–96)</td>
<td>64 (48–92)</td>
<td>0.902</td>
</tr>
<tr>
<td>In-hospital mortality</td>
<td>6 (8.5)</td>
<td>39 (5.2)</td>
<td>0.254</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1741826711428243"><p>Values are median (25–75th percentile) or <italic>n</italic> (%). <sup>a</sup><italic>p</italic> &lt; 0.05 (3 vessels vs. 1 and 2 vessels). <sup>b</sup>Fisher’s exact test.</p></fn>
<fn id="table-fn2-1741826711428243"><p>AMI, acute myocardial infarction; CABG, coronary artery bypass graft; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate; LM, left main coronary artery; MI, myocardial infarction; PCI, percutaneous coronary intervention.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>As depicted in <xref ref-type="table" rid="table2-1741826711428243">Table 2</xref>, no difference was observed in the use of devices in COPD patients when compared to patients without COPD. Norepinephrine and dopamine was more frequently used in COPD patients (<italic>p</italic> = 0.020 and 0.048, respectively).
<table-wrap id="table2-1741826711428243" position="float"><label>Table 2.</label><caption><p>Use of devices and inotropic drugs in our population</p></caption>
<graphic alternate-form-of="table2-1741826711428243" xlink:href="10.1177_1741826711428243-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>COPD (<italic>n</italic> = 71)</th>
<th>No COPD (<italic>n</italic> = 747)</th>
<th><italic>p</italic>-value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Mechanical ventilation</td>
<td>11 (15.5)</td>
<td>76 (10.2)</td>
<td>0.165</td>
</tr>
<tr>
<td>CVVHDF</td>
<td>6 (8.5)</td>
<td>24 (3.2)</td>
<td>0.077<sup><xref ref-type="table-fn" rid="table-fn3-1741826711428243">a</xref></sup></td>
</tr>
<tr>
<td>IABP</td>
<td>15 (21.1)</td>
<td>173 (23.2)</td>
<td>0.697</td>
</tr>
<tr>
<td>Inotropic agents</td>
</tr>
<tr>
<td> Norepinephrine</td>
<td>8 (11.3)</td>
<td>33 (4.4)</td>
<td>0.020</td>
</tr>
<tr>
<td> Dobutamine</td>
<td>3 (4.2)</td>
<td>27 (3.6)</td>
<td>0.739</td>
</tr>
<tr>
<td> Dopamine</td>
<td>14 (19.7)</td>
<td>87 (11.6)</td>
<td>0.048</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-1741826711428243"><p>Values are <italic>n</italic> (%). <sup>a</sup>Fisher’s exact test.</p></fn>
<fn id="table-fn4-1741826711428243"><p>COPD, chronic obstructive pulmonary disease; CVVHDF, continuous venous−venous haemodiafiltration; IABP, intra-aortic balloon pump.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>No difference was observed in Killip class in the comparison between patients with COPD and those without (<xref ref-type="table" rid="table3-1741826711428243">Table 3</xref>). The incidence of cardiogenic shock was comparable between the two subgroups (COPD, 9.9%; non-COPD, 8.1%; <italic>p</italic> = 0.592). Patients with COPD showed higher values of NT-pro-BNP (<italic>p</italic> = 0.004), uric acid (<italic>p</italic> = 0.005), erythrocyte sedimentation rate (ESR; <italic>p</italic> = 0.002), fibrinogen (<italic>p</italic> = 0.004), and CRP positivity (<italic>p</italic> = 0.017).
<table-wrap id="table3-1741826711428243" position="float"><label>Table 3.</label><caption><p>Comparison between ST-elevation myocardial infarction patients with and without chronic obstructive pulmonary disease (COPD)</p></caption>
<graphic alternate-form-of="table3-1741826711428243" xlink:href="10.1177_1741826711428243-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>COPD (<italic>n</italic> = 71)</th>
<th>No COPD (<italic>n</italic> = 747)</th>
<th><italic>p</italic>-value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Clinical data</td>
</tr>
<tr>
<td> Body mass index (kg/m<sup>2</sup>)</td>
<td>26.0 (23.1–28.6)</td>
<td>25.9 (23.7–28.1)</td>
<td>0.644</td>
</tr>
<tr>
<td> Killip class</td>
</tr>
<tr>
<td>  I−II</td>
<td>63 (88.7)</td>
<td>663 (88.8)</td>
<td>0.995</td>
</tr>
<tr>
<td>  III−IV</td>
<td>8 (11.3)</td>
<td>84 (11.2)</td>
</tr>
<tr>
<td> Major bleeding</td>
<td>14 (19.7)</td>
<td>123 (16.5)</td>
<td>0.483</td>
</tr>
<tr>
<td>Laboratory data</td>
</tr>
<tr>
<td> Admission glucose (mg/dl)</td>
<td>139 (114–212)</td>
<td>132 (114–168)</td>
<td>0.317</td>
</tr>
<tr>
<td> Peak glucose (mg/dl)</td>
<td>168 (138–216)</td>
<td>154 (129–196)</td>
<td>0.097</td>
</tr>
<tr>
<td> Insulinaemia (IU/l)</td>
<td>8.1 (5.1–18.0)</td>
<td>9.5 (5.6–17.5)</td>
<td>0.637</td>
</tr>
<tr>
<td> C-peptide (IU/l)</td>
<td>1.11 (0.69–0.27)</td>
<td>1.02 (0.68–1.27)</td>
<td>0.690</td>
</tr>
<tr>
<td> HOMA index positivity</td>
<td>9 (18.4)</td>
<td>79 (15.5)</td>
<td>0.597</td>
</tr>
<tr>
<td> AST (IU/l)</td>
<td>48 (31–117)</td>
<td>74 (38–162)</td>
<td>0.022</td>
</tr>
<tr>
<td> ALT (IU/l)</td>
<td>40 (21–81)</td>
<td>39 (24–69)</td>
<td>0.878</td>
</tr>
<tr>
<td> GGT (IU/l)</td>
<td>25 (15–47)</td>
<td>29 (20–45.5)</td>
<td>0.231</td>
</tr>
<tr>
<td> Peak TnI (ng/ml)</td>
<td>54.1 (28.7–212)</td>
<td>92.2 (44.1–186.0)</td>
<td>0.084</td>
</tr>
<tr>
<td> NT-pro-BNP (pg/ml)</td>
<td>2884 (921–7200)</td>
<td>1375 (530–3414)</td>
<td>0.004</td>
</tr>
<tr>
<td> Uric acid (mg/dl)</td>
<td>6.2 (4.8–7.9)</td>
<td>5.5 (4.6–6.5)</td>
<td>0.005</td>
</tr>
<tr>
<td> ESR</td>
<td>32.5 (22.8–52.5)</td>
<td>25 (14–41)</td>
<td>0.002</td>
</tr>
<tr>
<td> CRP (mg/dl)</td>
<td>17 (9–60)</td>
<td>10 (8–23)</td>
<td>0.008</td>
</tr>
<tr>
<td> Positive CRP</td>
<td>41 (68.3)</td>
<td>331 (52.3)</td>
<td>0.017</td>
</tr>
<tr>
<td> Leucocytes (10<sup>3</sup>/µl)</td>
<td>10.4 (8.9–13.2)</td>
<td>11.0 (8.9–13.8)</td>
<td>0.670</td>
</tr>
<tr>
<td> Fibrinogen (mg/dl)</td>
<td>434 (345–546)</td>
<td>391 (334–467)</td>
<td>0.004</td>
</tr>
<tr>
<td> Total cholesterol (mg/dl)</td>
<td>171 (146–201)</td>
<td>185 (156–216</td>
<td>0.021</td>
</tr>
<tr>
<td> HDL cholesterol</td>
<td>40 (34–47)</td>
<td>41 (35–47)</td>
<td>0.555</td>
</tr>
<tr>
<td> LDL cholesterol</td>
<td>107 (87–133)</td>
<td>118 (96–147)</td>
<td>0.009</td>
</tr>
<tr>
<td> Triglycerides (mg/dl)</td>
<td>94 (71–124)</td>
<td>101 (77–140)</td>
<td>0.251</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-1741826711428243"><p>Values are median (25−75th percentile) or <italic>n</italic> (%).</p></fn>
<fn id="table-fn6-1741826711428243"><p>ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; GGT, gamma-glutamyl transferase; HDL, high-density lipoprotein; HOMA, homeostatic model assessment; LDL, low-density lipoprotein; NT-pro-BNP, N-terminal pro-brain natriuretic peptide; TnI, troponin I.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>As shown in <xref ref-type="table" rid="table4-1741826711428243">Table 4</xref>, on admission COPD patients were less frequently on β-blockers (<italic>p</italic> &lt; 0.001) and on IIbIIIa glycoprotein inhibitors (<italic>p</italic> = 0.036) and at discharge β-blockers were less frequently administered to COPD patients. No other significant difference in drug administration was observed between COPD and non-COPD patients.
<table-wrap id="table4-1741826711428243" position="float"><label>Table 4.</label><caption><p>Medications in ST-elevation myocardial infarction patients with and without chronic obstructive pulmonary disease (COPD)</p></caption>
<graphic alternate-form-of="table4-1741826711428243" xlink:href="10.1177_1741826711428243-table4.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>COPD</th>
<th>No COPD</th>
<th><italic>p</italic>-value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Admission</td>
<td><italic>n</italic> = 71</td>
<td><italic>n</italic> = 747</td>
</tr>
<tr>
<td> β-blockers</td>
<td>50 (70.4)</td>
<td>638 (85.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td> ACEi/ARB</td>
<td>61 (85.9)</td>
<td>660 (88.4)</td>
<td>0.544</td>
</tr>
<tr>
<td> Ca channel blockers</td>
<td>6 (8.4)</td>
<td>26 (3.5)</td>
<td>0.102<sup><xref ref-type="table-fn" rid="table-fn7-1741826711428243">a</xref></sup></td>
</tr>
<tr>
<td> Diuretics</td>
<td>57 (80.3)</td>
<td>551 (73.8)</td>
<td>0.312</td>
</tr>
<tr>
<td> ASA</td>
<td>69 (97.2)</td>
<td>716 (95.9)</td>
<td>1<sup><xref ref-type="table-fn" rid="table-fn7-1741826711428243">a</xref></sup></td>
</tr>
<tr>
<td> Clopidogrel</td>
<td>70 (98.6)</td>
<td>725 (97.0)</td>
<td>0.713<sup><xref ref-type="table-fn" rid="table-fn7-1741826711428243">a</xref></sup></td>
</tr>
<tr>
<td> IIbIIIa GP inhibitors</td>
<td>42 (59.2)</td>
<td>531 (71.1)</td>
<td>0.036</td>
</tr>
<tr>
<td>At discharge</td>
<td><italic>n</italic> = 65</td>
<td><italic>n</italic> = 708</td>
</tr>
<tr>
<td> β-blockers</td>
<td>43 (66.2)</td>
<td>609 (86.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td> ACEi/ARB</td>
<td>56 (86.2)</td>
<td>629 (88.8)</td>
<td>0.514</td>
</tr>
<tr>
<td> Ca channel blockers</td>
<td>5 (7.7)</td>
<td>16 (2.3)</td>
<td>0.051<sup><xref ref-type="table-fn" rid="table-fn7-1741826711428243">a</xref></sup></td>
</tr>
<tr>
<td> Diuretics</td>
<td>44 (67.7)</td>
<td>394 (55.6)</td>
<td>0.061</td>
</tr>
<tr>
<td> ASA</td>
<td>64 (98.5)</td>
<td>675 (95.3)</td>
<td>0.403<sup><xref ref-type="table-fn" rid="table-fn7-1741826711428243">a</xref></sup></td>
</tr>
<tr>
<td> Clopidogrel</td>
<td>62 (95.4)</td>
<td>665 (93.9)</td>
<td>0.893<sup><xref ref-type="table-fn" rid="table-fn7-1741826711428243">a</xref></sup></td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1741826711428243"><label>a</label>
<p>Fisher’s exact test.</p></fn>
<fn id="table-fn8-1741826711428243"><p>ACEi, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; ASA, acetylsalicylic acid; GP, glycoprotein.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>At multivariate analysis, COPD is not associated with an increased risk for in-ICCU death (odds ratio 1.68, 95% CI 0.68–4.11, <italic>p</italic> = 0.259).</p>
<p>At follow up (median 37.3, interquartile range 17.8–53.8) months), Kaplan−Meier survival curve documented a significantly worse outcome in COPD patients (<xref ref-type="fig" rid="fig1-1741826711428243">Figure 1</xref>). When age was taken into account (<xref ref-type="fig" rid="fig2-1741826711428243">Figure 2</xref>), COPD patients aged &lt;75 years showed a significantly worse outcome at follow up when compared to no-COPD patients aged &lt;75 years. Among patients aged ≥75 years, no significant difference in outcome at follow up was detectable between COPD and no-COPD patients (<xref ref-type="fig" rid="fig2-1741826711428243">Figure 2</xref>).
<fig id="fig1-1741826711428243" position="float"><label>Figure 1.</label><caption><p>Survival rates in patients with and without chronic obstructive pulmonary disease (COPD).</p></caption><graphic xlink:href="10.1177_1741826711428243-fig1.tif"/>
</fig>
<fig id="fig2-1741826711428243" position="float"><label>Figure 2.</label><caption><p>Survival rates in patients with and without chronic obstructive pulmonary disease (COPD) according to age.</p></caption><graphic xlink:href="10.1177_1741826711428243-fig2.tif"/>
</fig></p>
<p>At multivariate analysis, the following variables were independent predictors for death at follow up: age (hazard ratio, HR 1.076, 95% CI 1.047−1.106; <italic>p</italic> &lt; 0.001; Wald 27.777), eGFR (HR 0.981, 95% CI 0.970–0.993; <italic>p</italic> &lt; 0.001; Wald 10.599), COPD (HR 2.401, 95% CI 1.358–4.247; <italic>p</italic> = 0.003; Wald 9.068), discharge LVEF (HR 0.964, 95% CI 0.940–0.990; <italic>p</italic> = 0.006; Wald 7.561).</p>
</sec>
<sec id="sec6-1741826711428243" sec-type="discussion"><title>Discussion</title>
<p>The main finding of the present investigation, performed in consecutive STEMI patients all submitted to PCI, is that while the presence of COPD was not significantly associated with an increased early mortality, COPD is an independent predictor of long-term mortality. In particular, long-term survival was significantly poorer in COPD patients &lt;75 years in respect to no-COPD patients with the same age. Among patients aged ≥75 years no difference in survival rate was detectable at long term between COPD and no-COPD patients.</p>
<p>Data on the impact of COPD on early death in patients with AMI are conflicting. In a large cohort of AMI patients, Behar et al.<sup><xref ref-type="bibr" rid="bibr2-1741826711428243">2</xref></sup> documented that COPD was not independently associated with either in-hospital or post-discharge excess fatality rates. In a prospective, multicentre, multinational study of 8167 consecutive patients hospitalized with acute coronary syndrome, the presence of COPD was associated with higher risk of heart failure and major bleeding complications without increased risk of in-hospital mortality.<sup><xref ref-type="bibr" rid="bibr24-1741826711428243">24</xref></sup> Conversely, Wakabayashi et al.<sup><xref ref-type="bibr" rid="bibr23-1741826711428243">23</xref></sup> assessed the impact of COPD on acute-phase outcome of 3249 consecutive patients with STEMI who underwent primary or rescue PCI. Patients with COPD had higher rates of the composite end point of death or cardiogenic shock and, after multivariate analysis, COPD remained a strong independent predictor of the composite end point of death or cardiogenic shock. Discrepancies with our investigation may be related to the different sample size and to the fact that the authors evaluated the composite end point of death or cardiogenic shock. Moreover, the study by Wakabayashi et al.<sup><xref ref-type="bibr" rid="bibr23-1741826711428243">23</xref></sup> was retrospective, while we prospecively investigated the impact of COPD in our population. Similarly to Wakabayashi et al.<sup><xref ref-type="bibr" rid="bibr23-1741826711428243">23</xref></sup> and to previous reports,<sup><xref ref-type="bibr" rid="bibr2-1741826711428243">2</xref><xref ref-type="bibr" rid="bibr3-1741826711428243"/><xref ref-type="bibr" rid="bibr4-1741826711428243"/>–<xref ref-type="bibr" rid="bibr5-1741826711428243">5</xref>,<xref ref-type="bibr" rid="bibr24-1741826711428243">24</xref></sup> in our series COPD patients were older, were more frequently smokers, had reduced renal failure, and were characterized by a higher inflammatory activation as indicated by higher values of ESR, fibrinogen, and CRP.</p>
<p>The impact of COPD on long-term mortality has been previously investigated. In an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)<sup><xref ref-type="bibr" rid="bibr5-1741826711428243">5</xref></sup> enrolling patients with myocardial infarction complicated by left ventricular systolic dysfunction, heart failure, or both, treated with mechanical revascularization or thrombolysis, COPD was associated with increased mortality and non-fatal clinical events at follow up. In a prospectively study enrolling 2481 patients presenting with myocardial infarction<sup><xref ref-type="bibr" rid="bibr4-1741826711428243">4</xref></sup> [for the Prospective Registry Evaluating Myocardial Infarction: Event and Recovery (PREMIER) study], patients with COPD had greater mortality, higher rehospitalization rates, and poorer health status 1 year after a myocardial infarction. However, PCI was performed less frequently in COPD patients. Conversely, in the study by Koller et al.,<sup><xref ref-type="bibr" rid="bibr3-1741826711428243">3</xref></sup> COPD is a predictor of long-term mortality only in patients with AMI without congestive heart failure.</p>
<p>In our series, COPD was an independent predictor of long-term mortality, but a lower survival rate was detectable only in COPD patients aged &lt;75 years in respect to no-COPD patients with the same age. The role of age in the risk stratification of COPD patients has been previously reported in the Kaiser programme, which found a stronger relationship of COPD to CVD outcomes in patients &lt;65 years of age, suggesting that CVD risk should be monitored and treated with particular care in younger adults with COPD.<sup><xref ref-type="bibr" rid="bibr6-1741826711428243">6</xref></sup> A higher prevalence of cigarette smoking in younger patients may account for this phenomenon.<sup><xref ref-type="bibr" rid="bibr6-1741826711428243">6</xref></sup></p>
<sec id="sec7-1741826711428243"><title>Study limitation</title>
<p>In our study, there is no information on COPD severity, medication, and the incidence of COPD readmission. These data could have helped for a better risk stratification but detailed assessment of the severity of pulmonary disease was not possible in our patients, since in the acute phase of STEMI. However, our investigation comprises a large series of COPD patients with STEMI, all submitted to primary angioplasty, consecutively admitted to a single centre. Nevertheless, further studies (possibly a multicentre trial) are needed to better elucidate the prognostic role of COPD in STEMI, focusing on disease severity.</p>
<p>In conclusion, in consecutive STEMI patients all submitted to PCI, the presence of COPD is not associated with a significantly increased in-hospital mortality. Conversely, at long term, COPD patients aged &lt;75 years show a poorer survival rate, thus representing a subgroup at higher risk. Our data strongly suggest that age should be taken into account in the risk stratification of COPD patients with STEMI.</p>
</sec>
</sec>
</body>
<back>
<sec id="sec8-1741826711428243"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<ref-list><title>References</title>
<ref id="bibr1-1741826711428243"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>MK</given-names></name><name><surname>McLaughlin</surname><given-names>VV</given-names></name><name><surname>Criner</surname><given-names>GJ</given-names></name><name><surname>Martinez</surname><given-names>FJ</given-names></name></person-group>. <article-title>Pulmonary diseases and the heart</article-title>. <source>Circulation</source> <year>2007</year>; <volume>116</volume>(<issue>25</issue>): <fpage>2992</fpage>–<lpage>3005</lpage>.</citation></ref>
<ref id="bibr2-1741826711428243"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Behar</surname><given-names>S</given-names></name><name><surname>Panosh</surname><given-names>A</given-names></name><name><surname>Reicher-Reiss</surname><given-names>H</given-names></name><name><surname>Zion</surname><given-names>M</given-names></name><name><surname>Schlesinger</surname><given-names>Z</given-names></name><name><surname>Goldbourt</surname><given-names>U</given-names></name></person-group>. <article-title>Prevalence and prognosis of chronic obstructive pulmonary disease among 5,839 consecutive patients with acute myocardial infarction</article-title>. <source>SPRINT Study Group. <italic>Am J Med</italic></source> <year>1992</year>; <volume>93</volume>: <fpage>637</fpage>–<lpage>641</lpage>.</citation></ref>
<ref id="bibr3-1741826711428243"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kjøller</surname><given-names>E</given-names></name><name><surname>Køber</surname><given-names>L</given-names></name><name><surname>Iversen</surname><given-names>K</given-names></name><name><surname>Torp-Pedersen</surname><given-names>C</given-names></name></person-group>. <collab>Trace Study Group</collab>. <article-title>Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction</article-title>. <source>Eur J Heart Fail</source> <year>2004</year>; <volume>6</volume>: <fpage>71</fpage>–<lpage>77</lpage>.</citation></ref>
<ref id="bibr4-1741826711428243"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salisbury</surname><given-names>AC</given-names></name><name><surname>Reid</surname><given-names>KJ</given-names></name><name><surname>Spertus</surname><given-names>JA</given-names></name></person-group>. <article-title>Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes</article-title>. <source>Am J Cardiol</source> <year>2007</year>; <volume>99</volume>: <fpage>636</fpage>–<lpage>641</lpage>.</citation></ref>
<ref id="bibr5-1741826711428243"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawkins</surname><given-names>NM</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Pieper</surname><given-names>KS</given-names></name><name><surname>Solomon</surname><given-names>SD</given-names></name><name><surname>Kober</surname><given-names>L</given-names></name><name><surname>Velazquez</surname><given-names>EJ</given-names></name><etal/></person-group>. <collab>Valsartan in Acute Myocardial Infarction Trial investigators</collab>. <article-title>Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction</article-title>. <source>Eur J Heart Fail</source> <year>2009</year>; <volume>11</volume>: <fpage>292</fpage>–<lpage>298</lpage>.</citation></ref>
<ref id="bibr6-1741826711428243"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sidney</surname><given-names>S</given-names></name><name><surname>Sorel</surname><given-names>M</given-names></name><name><surname>Quesenberry</surname><given-names>CP</given-names><suffix>Jr</suffix></name><name><surname>DeLuise</surname><given-names>C</given-names></name><name><surname>Lanes</surname><given-names>S</given-names></name><name><surname>Eisner</surname><given-names>MD</given-names></name></person-group>. <article-title>COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program</article-title>. <source>Chest</source> <year>2005</year>; <volume>128</volume>: <fpage>2068</fpage>–<lpage>2075</lpage>.</citation></ref>
<ref id="bibr7-1741826711428243"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Valente</surname><given-names>S</given-names></name><name><surname>Lazzeri</surname><given-names>C</given-names></name><name><surname>Chiostri</surname><given-names>M</given-names></name><name><surname>Giglioli</surname><given-names>C</given-names></name><name><surname>Sori</surname><given-names>A</given-names></name><name><surname>Tigli</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>NT-proBNP on admission for early risk stratification in STEMI patients submitted to PCI. Relation with extension of STEMI and inflammatory markers</article-title>. <source>Int J Cardiol</source> <year>2009</year>; <volume>132</volume>(<issue>1</issue>): <fpage>84</fpage>–<lpage>89</lpage>.</citation></ref>
<ref id="bibr8-1741826711428243"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lazzeri</surname><given-names>C</given-names></name><name><surname>Sori</surname><given-names>A</given-names></name><name><surname>Chiostri</surname><given-names>M</given-names></name><name><surname>Gensini</surname><given-names>GF</given-names></name><name><surname>Valente</surname><given-names>S</given-names></name></person-group>. <article-title>Prognostic role of insulin resistance as assessed by homeostatic model assessment index in the acute phase of myocardial infarction in nondiabetic patients submitted to percutaneous coronary intervention</article-title>. <source>Eur J Anaesthesiol</source> <year>2009</year>; <volume>26</volume>(<issue>10</issue>): <fpage>856</fpage>–<lpage>862</lpage>.</citation></ref>
<ref id="bibr9-1741826711428243"><label>9</label><citation citation-type="other"><comment>Valente S, Lazzeri C, Chiostri M, Giglioli C, Zucchini M, Grossi F, et al. Gender-related difference in ST-elevation myocardial infarction treated with primary angioplasty: a single-centre 6-year registry. <italic>Eur J Cardiovasc Prev Rehabil</italic> 9 March 2011 [Epublication ahead of print]</comment>.</citation></ref>
<ref id="bibr10-1741826711428243"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lazzeri</surname><given-names>C</given-names></name><name><surname>Valente</surname><given-names>S</given-names></name><name><surname>Chiostri</surname><given-names>M</given-names></name><name><surname>Picariello</surname><given-names>C</given-names></name><name><surname>Gensini</surname><given-names>GF</given-names></name></person-group>. <article-title>Correlates of acute insulin resistance in the early phase of non-diabetic ST-elevation myocardial infarction</article-title>. <source>Diab Vasc Dis Res</source> <year>2011</year>; <volume>8</volume>(<issue>1</issue>): <fpage>35</fpage>–<lpage>42</lpage>.</citation></ref>
<ref id="bibr11-1741826711428243"><label>11</label><citation citation-type="other"><comment>Lazzeri C, Valente S, Chiostri M, Picariello C and Gensini GF. Lactate in the acute phase of ST-elevation myocardial infarction treated with mechanical revascularization A single-center experience. <italic>Am J Emerg Med</italic> 23 November 2010 [Epublication ahead of print]</comment>.</citation></ref>
<ref id="bibr12-1741826711428243"><label>12</label><citation citation-type="journal"><collab>Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI), Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, et al</collab>. <article-title>Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)</article-title>. <source>Eur Heart J</source> <year>2010</year>; <volume>31</volume>(<issue>20</issue>): <fpage>2501</fpage>–<lpage>2555</lpage>.</citation></ref>
<ref id="bibr13-1741826711428243"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van de Werf</surname><given-names>F</given-names></name><name><surname>Bax</surname><given-names>J</given-names></name><name><surname>Betriu</surname><given-names>A</given-names></name><name><surname>Blomstrom-Lundqvist</surname><given-names>C</given-names></name><name><surname>Crea</surname><given-names>F</given-names></name><name><surname>Falk</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology</article-title>. <source>Eur Heart J</source> <year>2008</year>; <volume>29</volume>(<issue>23</issue>): <fpage>2909</fpage>–<lpage>2945</lpage>.</citation></ref>
<ref id="bibr14-1741826711428243"><label>14</label><citation citation-type="other"><comment>Lazzeri C, Valente S, Chiostri M, Picariello C and Gensini GF. Uric acid in the early risk stratification of ST-elevation myocardial infarction. <italic>Intern Emerg Med</italic> 15 January 2011 [Epublication ahead of print]</comment>.</citation></ref>
<ref id="bibr15-1741826711428243"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lazzeri</surname><given-names>C</given-names></name><name><surname>Valente</surname><given-names>S</given-names></name><name><surname>Tarquini</surname><given-names>R</given-names></name><name><surname>Chiostri</surname><given-names>M</given-names></name><name><surname>Picariello</surname><given-names>C</given-names></name><name><surname>Gensini</surname><given-names>GF</given-names></name></person-group>. <article-title>Prognostic values of admission transaminases in ST-elevation myocardial infarction submitted to primary angioplasty</article-title>. <source>Med Sci Monit</source> <year>2010</year>; <volume>16</volume>(<issue>12</issue>): <fpage>CR567</fpage>–<lpage>CR574</lpage>.</citation></ref>
<ref id="bibr16-1741826711428243"><label>16</label><citation citation-type="other"><comment>Lazzeri C, Valente S, Tarquini R, Chiostri M, Picariello C and Gensini GF. The prognostic role of gamma-glutamyltransferase activity in non-diabetic ST-elevation myocardial infarction. <italic>Intern Emerg Med</italic> 2011; 6(3): 213–219</comment>.</citation></ref>
<ref id="bibr17-1741826711428243"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Levey</surname><given-names>AS</given-names></name><name><surname>Stevens</surname><given-names>LA</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><name><surname>Zhang</surname><given-names>YL</given-names></name><name><surname>Castro</surname><given-names>AF</given-names><suffix>III</suffix></name><name><surname>Feldman</surname><given-names>HI</given-names></name><etal/></person-group>. <article-title>A new equation to estimate glomerular filtration rate</article-title>. <source>Ann Intern Med</source> <year>2009</year>; <volume>150</volume>(<issue>9</issue>): <fpage>604</fpage>–<lpage>612</lpage>.</citation></ref>
<ref id="bibr18-1741826711428243"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lazzeri</surname><given-names>C</given-names></name><name><surname>Valente</surname><given-names>S</given-names></name><name><surname>Chiostri</surname><given-names>M</given-names></name><name><surname>Picariello</surname><given-names>C</given-names></name><name><surname>Gensini</surname><given-names>GF</given-names></name></person-group>. <article-title>In-hospital peak glycemia and prognosis in STEMI patients without earlier known diabetes</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source> <year>2010</year>; <volume>17</volume>(<issue>4</issue>): <fpage>419</fpage>–<lpage>423</lpage>.</citation></ref>
<ref id="bibr19-1741826711428243"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balkau</surname><given-names>B</given-names></name><name><surname>Charles</surname><given-names>M</given-names></name></person-group>. <article-title>Comment on the provisional report from the WHO Consultation. European Group for the Study of Insulin Resistance (EGIR)</article-title>. <source>Diabet Med</source> <year>1999</year>; <volume>16</volume>: <fpage>442</fpage>–<lpage>443</lpage>.</citation></ref>
<ref id="bibr20-1741826711428243"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lazzeri</surname><given-names>C</given-names></name><name><surname>Valente</surname><given-names>S</given-names></name><name><surname>Chiostri</surname><given-names>M</given-names></name><name><surname>Picariello</surname><given-names>C</given-names></name><name><surname>Gensini</surname><given-names>GF</given-names></name></person-group>. <article-title>Acute glucose dysmetabolism in the early phase of ST-elevation myocardial infarction: the age response</article-title>. <source>Diabet Vasc Dis Res</source> <year>2010</year>; <volume>7</volume>(<issue>2</issue>): <fpage>131</fpage>–<lpage>137</lpage>.</citation></ref>
<ref id="bibr21-1741826711428243"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cerqueira</surname><given-names>MD</given-names></name><name><surname>Weissman</surname><given-names>NJ</given-names></name><name><surname>Dilsizian</surname><given-names>V</given-names></name><name><surname>Jacobs</surname><given-names>AK</given-names></name><name><surname>Kaul</surname><given-names>S</given-names></name><name><surname>Laskey</surname><given-names>WK</given-names></name><etal/></person-group>. <collab>American Heart Association Writing Group on Myocardial Segmentation and Registration for Cardiac Imaging</collab>. <article-title>Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: a statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association</article-title>. <source>Circulation</source> <year>2002</year>; <volume>105</volume>(<issue>4</issue>): <fpage>539</fpage>–<lpage>542</lpage>.</citation></ref>
<ref id="bibr22-1741826711428243"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>White</surname><given-names>HD</given-names></name><name><surname>Ohman</surname><given-names>EM</given-names></name><name><surname>Bertrand</surname><given-names>ME</given-names></name><name><surname>Lincoff</surname><given-names>AM</given-names></name><name><surname>McLaurin</surname><given-names>BT</given-names></name><etal/></person-group>. <collab>Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial Investigators</collab>. <article-title>Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial</article-title>. <source>Lancet</source> <year>2007</year>; <volume>369</volume>: <fpage>907</fpage>–<lpage>919</lpage>.</citation></ref>
<ref id="bibr23-1741826711428243"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wakabayashi</surname><given-names>K</given-names></name><name><surname>Gonzalez</surname><given-names>MA</given-names></name><name><surname>Delhaye</surname><given-names>C</given-names></name><name><surname>Ben-Dor</surname><given-names>I</given-names></name><name><surname>Maluenda</surname><given-names>G</given-names></name><name><surname>Collins</surname><given-names>SD</given-names></name><etal/></person-group>. <article-title>Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction</article-title>. <source>Am J Cardiol</source> <year>2010</year>; <volume>106</volume>(<issue>3</issue>): <fpage>305</fpage>–<lpage>309</lpage>.</citation></ref>
<ref id="bibr24-1741826711428243"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hadi</surname><given-names>HA</given-names></name><name><surname>Zubaid</surname><given-names>M</given-names></name><name><surname>Al Mahmeed</surname><given-names>W</given-names></name><name><surname>El-Menyar</surname><given-names>AA</given-names></name><name><surname>Ridha</surname><given-names>M</given-names></name><name><surname>Alsheikh-Ali</surname><given-names>AA</given-names></name><etal/></person-group>. <article-title>Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 Middle Eastern patients with acute coronary syndrome</article-title>. <source>Clin Cardiol</source> <year>2010</year>; <volume>33</volume>(<issue>4</issue>): <fpage>228</fpage>–<lpage>235</lpage>.</citation></ref>
</ref-list>
</back>
</article>